Related Experiment Video

Updated: Jun 23, 2026

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

CD59 blockade enhances antigen-specific CD4+ T cell responses in humans: a new target for cancer immunotherapy?

Baalasubramanian Sivasankar1, M Paula Longhi, Kathleen M E Gallagher

  • 1Department of Medical Biochemistry and Immunology, Henry Wellcome Building, School of Medicine, Cardiff University, Heath Park, Cardiff, UK.

Journal of Immunology (Baltimore, Md. : 1950)
|April 22, 2009
PubMed

Insights

CD59, a molecule that regulates immune responses, is upregulated on activated human CD4(+) T cells. Blocking CD59 enhances T cell activity, showing potential for boosting anti-cancer immunity.

Area of Science:

  • Immunology
  • Molecular Biology
  • Cellular Biology

Background:

  • CD59 is a GPI-anchored molecule regulating complement cascade.
  • Previous studies showed mouse CD59 down-modulates CD4(+) T cell activity.
  • The role of CD59 on human T cells required further investigation.

Purpose of the Study:

  • To investigate the function of CD59 on human CD4(+) T cells.
  • To explore the therapeutic potential of targeting CD59 in cancer immunotherapy.

Main Methods:

  • Analyzing CD59 expression on activated human CD4(+) T cells.
  • Assessing the impact of CD59 blockade on T cell responses to polyclonal and antigen-specific stimulation.
  • Evaluating T cell responses from colorectal cancer patients.

Main Results:

  • CD59 is upregulated on activated human CD4(+) T cells.
  • CD59 down-modulates CD4(+) T cell activity upon stimulation.
  • Blocking CD59 significantly enhanced CD4(+) T cell responses to tumor antigens in cancer patients.

Conclusions:

  • CD59 acts as a negative regulator of human CD4(+) T cell activity.
  • Targeting CD59 offers a potential strategy to enhance anti-tumor immune responses in cancer patients.
  • Modulating CD59 expression may boost weakened immune responses in conditions like cancer.

More Related Videos

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells12:16

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses10:13

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...